Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Proteomics’ early detection test for endometriosis potentially a game changer

  • In News
  • April 3, 2023
  • Tony Farnham
Proteomics’ early detection test for endometriosis potentially a game changer

Endometriosis is a chronic disease where tissue similar to the lining of the uterus grows outside the uterus. Women are susceptible to this disease over a significant portion of their lives, starting with their first menstrual period, extending through until menopause. For all the advances in medical science, the disease has no known cure. Even its cause(s) are still not fully understood. The incidence of endometriosis is quite high, with it affecting one in nine women and girls. And its financial cost to the Australian economy is immense, with Endometriosis Australia citing a figure of almost $10 billion (with around two-thirds attributed to a lost productivity and the remainder direct healthcare costs).

Over the years, efforts by health care professionals to diagnose a patient with this disease have been complicated and time consuming. This because sufferers of endometriosis often present with symptoms that could be caused by a host of other ailments.

These symptoms could be pain accompanying normal body functions like periods, sexual intercourse, bowel movements and/or urination. Chronic pelvic pain, abdominal bloating, nausea and fatigue also often present in sufferers. Then there is the damage done to the mental state of sufferers, with some enduring depression and anxiety. Further complicating diagnosis of the disease, some sufferers exhibit no symptoms at all.

And on top of all the suffering caused by endometriosis, it can also potentially make it harder for women to start families.

At least accurate early detection of endometriosis is close at hand

While endometriosis has no cure, the symptoms of the disease are treatable. And, like so many other incurable diseases, the quicker endometriosis is diagnosed, the better the chance of more effectively lessening the health consequences of its symptoms.

Unfortunately, for all too long, an accurate early detection test for endometriosis was as elusive pipedream. Sufferers endured many years – in many cases seven years and longer – of testing before they were diagnosed with the disease. These long-time testing methods were also found to have sub-par accuracy levels. This meant patients remained in an extended state of flux before treatments were prescribed, which range from medicines all the way through to invasive surgical procedures.

But now a recent study has validated the effectiveness of a new game-changing early detection test for endometriosis.

Proteomics has unveiled a new blood test for endometriosis

ASX-listed biotech Proteomics International Laboratories (ASX:PIQ) has recently announced very promising results for a new blood test for diagnosing endometriosis (see ASX announcement dated 24 March 2023). These results were presented at the 70th Annual Meeting of the international Society for Reproductive Investigation held in March 2023. The simple test uses biomarkers—protein ‘fingerprints’ in the blood—to screen for the painful condition. The Company’s preferred prototype correctly identified up to 90% of patients when comparing moderate or severe endometriosis to symptomatic controls (no endometriosis) in a 901 person study.

Commenting on the study results, Proteomics International Managing Director Dr Richard Lipscombe said “We have a potential screening test for endometriosis—a simple blood test to help determine who should have an invasive laparoscopy and who should not. But the study also suggests the current gold standard for diagnosis—an invasive surgical procedure—may be misdiagnosing some patients, particularly in the early stages of endometriosis.”

Proteomics is now undertaking follow up research aimed at further proving up the effectiveness of its blood test, with Dr Lipscombe adding “We need to study more people in the early stages of endometriosis or with symptoms and to look more closely at their existing diagnosis.”

  • About
  • Latest Posts
Tony Farnham
Tony Farnham is a financial markets veteran and Analyst/Financial Writer at The Capital Network.
Latest posts by Tony Farnham (see all)
  • Carly Holdings’ EV Trial targets aspiring EV buyers - March 8, 2024
  • Careteq further penetrates its large and growing addressable market - August 31, 2023
  • Proteomics’ PromarkerD test enters the lucrative US market - May 10, 2023
  •  
  •  
  •  
  •  
  • asx piq
  • endometriosis
  • piq
  • Proteomics
  • richard lipscombe
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Tony Farnham
Tony Farnham is a financial markets veteran and Analyst/Financial Writer at The Capital Network.
Latest posts by Tony Farnham (see all)
  • Carly Holdings’ EV Trial targets aspiring EV buyers - March 8, 2024
  • Careteq further penetrates its large and growing addressable market - August 31, 2023
  • Proteomics’ PromarkerD test enters the lucrative US market - May 10, 2023

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Tony Farnham
Tony Farnham is a financial markets veteran and Analyst/Financial Writer at The Capital Network.
Latest posts by Tony Farnham (see all)
  • Carly Holdings’ EV Trial targets aspiring EV buyers - March 8, 2024
  • Careteq further penetrates its large and growing addressable market - August 31, 2023
  • Proteomics’ PromarkerD test enters the lucrative US market - May 10, 2023
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.